The Supreme Court has just blocked a $6 billion Purdue Pharma bankruptcy settlement that would protect the Sackler family from opioid-related civil claims

On Thursday, the Supreme Court halted Purdue Pharma's progress in its bankruptcy proceedings. The Biden administration had criticized this unusual arrangement, aimed at shielding the Sackler family from civil claims related to opioids.

The court not only agreed to temporarily stop the settlement but also announced its intention to examine the case and listen to arguments in December.

This situation emerged from the bankruptcy reorganization of Purdue Pharma, the maker of OxyContin. This reorganization was a response to litigation surrounding the company's alleged contribution to the opioid addiction crisis.

Until recently, the Sackler family had control over Purdue. Prior to the company's bankruptcy filing, they extracted billions of dollars from it. Now, the Sacklers have committed to contributing as much as $6 billion to Purdue's restructuring fund, under the condition that they are released from civil liability.

Purdue Pharma released a statement expressing confidence in the legality of their widely supported Plan of Reorganization. However, they expressed disappointment in the US Trustee's ability to single-handedly delay the release of billions of dollars meant for victim compensation, addressing the opioid crisis in communities nationwide, and providing overdose rescue medications.

Unusual Whales does not confirm the information's truthfulness or accuracy of the associated references, data, and cannot verify any of the information. Any content on this site or related pages are not intended to provide legal, tax, investment or insurance advice. Unusual Whales Inc. is not registered as a securities broker-dealer or an investment adviser with the U.S. Securities and Exchange Commission, the Financial Industry Regulatory Authority (“FINRA”) or any state securities regulatory authority. Nothing on Unusual Whales should be construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security by Unusual Whales or any third party. Options, investing, trading is risky, and losses are more expected than profits. Please do own research before investing. Please only subscribe after reading our full terms and understanding options and the market, and the inherent risks of trading. It is highly recommended not to trade on this, or any, information from Unusual Whales. Markets are risky, and you will likely lose some or all of your capital. Please check our terms for full details.
Any content on this site or related pages are not intended to provide legal, tax, investment or insurance advice. Unusual Whales Inc. is not registered as a securities broker-dealer or an investment adviser with the U.S. Securities and Exchange Commission, the Financial Industry Regulatory Authority (“FINRA”) or any state securities regulatory authority. Nothing on Unusual Whales should be construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security by Unusual Whales or any third party. Certain investment planning tools available on Unusual Whales may provide general investment education based on your input. You are solely responsible for determining whether any investment, investment strategy, security or related transaction is appropriate for you based on your personal investment objectives, financial circumstances and risk tolerance. You should consult your legal or tax professional regarding your specific situation. See terms for more information.